| Dr Cameo D Cozart-chance, MD | |
|
7300 Medical Center Dr, West Hills, CA 91307-1902 | |
| (818) 676-4999 | |
| Not Available |
| Full Name | Dr Cameo D Cozart-chance |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 23 Years |
| Location | 7300 Medical Center Dr, West Hills, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619903135 | NPI | - | NPPES |
| 405562400 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | D0061637 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| West Hills Hospital & Medical Center | West hills, CA | Hospital |
| Kaiser Foundation Hospital - Los Angeles | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Skilled Facility Health Care Solutions Inc | 9032299144 | 55 |
News Archive
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative (Evans, 4/18).
Computer-delivered and face-to-face interventions both can help curb problematic college drinking for a little while, but only in-person encounters produce results that last beyond a few months, according to a new analysis of the techniques schools use to counsel students on alcohol consumption.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 5 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative (Evans, 4/18).
Computer-delivered and face-to-face interventions both can help curb problematic college drinking for a little while, but only in-person encounters produce results that last beyond a few months, according to a new analysis of the techniques schools use to counsel students on alcohol consumption.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 5 days ago
| Entity Name | Skilled Facility Health Care Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104018423 PECOS PAC ID: 9032299144 Enrollment ID: O20080102000273 |
News Archive
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative (Evans, 4/18).
Computer-delivered and face-to-face interventions both can help curb problematic college drinking for a little while, but only in-person encounters produce results that last beyond a few months, according to a new analysis of the techniques schools use to counsel students on alcohol consumption.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 5 days ago
| Entity Name | Team Physicians Of Northern California Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649692716 PECOS PAC ID: 7113215146 Enrollment ID: O20161006002407 |
News Archive
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative (Evans, 4/18).
Computer-delivered and face-to-face interventions both can help curb problematic college drinking for a little while, but only in-person encounters produce results that last beyond a few months, according to a new analysis of the techniques schools use to counsel students on alcohol consumption.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cameo D Cozart-chance, MD 12813 Milbank St, Studio City, CA 91604-1354 Ph: (443) 286-8841 | Dr Cameo D Cozart-chance, MD 7300 Medical Center Dr, West Hills, CA 91307-1902 Ph: (818) 676-4999 |
News Archive
Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally. Revamilast is an orally active, potent and selective inhibitor of phosphodiesterase 4 (PDE 4) that is currently being developed by Glenmark for the treatment of chronic inflammatory disorders such as Asthma, Rheumatoid Arthritis (RA) and other inflammatory diseases.
The American Hospital Association is lobbying the CMS Innovation Center to make it easier for accountable care organizations to earn Medicare bonuses and delay potential penalties as the agency looks to expand the initiative (Evans, 4/18).
Computer-delivered and face-to-face interventions both can help curb problematic college drinking for a little while, but only in-person encounters produce results that last beyond a few months, according to a new analysis of the techniques schools use to counsel students on alcohol consumption.
A new report by the Substance Abuse and Mental Health Services Administration (SAMHSA) shows that people aged 12 to 49 who had used prescription pain relievers nonmedically were 19 times more likely to have initiated heroin use recently (within the past 12 months of being interviewed) than others in that age group (0.39 percent versus 0.02 percent).
› Verified 5 days ago
Gary Sindell, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 7300 Medical Center Dr, Emergency Department, West Hills, CA 91307 Phone: 818-676-4000 | |
Randall A Caldron, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 7230 Medical Center Dr, Suite 302, West Hills, CA 91307 Phone: 818-518-5980 Fax: 818-337-2049 | |
Loren E. Caira, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 7300 Medical Center Dr, Emergency Department, West Hills, CA 91307 Phone: 818-676-4000 | |
Alan L. Kuban, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7300 Medical Center Dr, Emergency Department, West Hills, CA 91307 Phone: 818-676-4000 | |
Ethan Qilong Han, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7300 Medical Center Dr, West Hills, CA 91307 Phone: 818-676-4000 | |
Jessica Shane Thomas, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7300 Medical Center Dr, West Hills, CA 91307 Phone: 818-676-4999 | |
Dr. Benjamin John Shannon-alferes, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7300 Medical Center Dr, West Hills, CA 91307 Phone: 818-676-4000 |